Prestige Consumer Healthcare Inc. (PBH) - Q1 2026 Summary
Business Context and Reporting Period
This summary covers the unaudited Form 10-Q for the quarterly period ended June 30, 2025 (First Quarter of Fiscal Year 2026). Prestige Consumer Healthcare Inc. develops, manufactures, and markets over-the-counter (OTC) health and personal care products in North America and international markets. The company operates as a holding company with no direct operations, relying on subsidiaries for manufacturing and distribution.
Key Financial Metrics
| Metric | Q1 2026 (Ended June 30, 2025) | Q1 2025 (Ended June 30, 2024) |
|---|---|---|
| Total Revenues | $249.5 million | $267.1 million |
| Gross Profit | $140.3 million (56.2% margin) | $146.0 million (54.7% margin) |
| Operating Income | $71.8 million | $72.0 million |
| Net Income | $47.5 million | $49.1 million |
| Diluted EPS | $0.95 | $0.98 |
| Operating Cash Flow | $79.0 million | $54.8 million |
| Cash and Equivalents | $139.5 million | $34.3 million |
| Long-Term Debt (Net) | $992.7 million | $992.4 million |
| Share Repurchases | $34.8 million | $26.0 million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 6.6% year-over-year. The North American segment declined 8.5%, primarily driven by a 35.9% drop in Eye & Ear Care sales due to supply shortages of the "Clear Eyes" brand. Conversely, the International segment grew 6.1%.
- Margin Expansion: Despite lower sales, gross margin improved to 56.2% from 54.7%, attributed to favorable product mix and reduced air freight costs.
- Cost Management: Advertising and marketing expenses decreased 11.2% to $34.9 million, and interest expense dropped 22.3% to $10.2 million due to lower average indebtedness and borrowing costs.
- Tax Rate Increase: The effective tax rate rose to 23.2% from 16.0%. The prior year benefited from a discrete release of a tax reserve due to statute of limitations expiring.
- Liquidity Improvement: Cash and cash equivalents increased by $41.6 million to $139.5 million, driven by strong operating cash flow ($79.0 million) and reduced financing outflows.
Outlook, Risks, and Unusual Items
- Supply Chain Constraints: Management highlights ongoing shortages of ingredients and products, particularly in eye care, which negatively impacted sales. Third-party manufacturers continue to face difficulties meeting demand.
- Acquisition Activity: The company entered a definitive agreement to acquire Pillar5 Pharma Inc., a sterile ophthalmic manufacturer, for approximately $100.0 million to expand eye care production capacity. Closing is expected in Q3 2026.
- Share Repurchases: The company continues its $300 million buyback program authorized in May 2024. Approximately $213.7 million remains available under the plan.
- Regulatory Changes: The "One Big Beautiful Bill Act" (OBBBA) was enacted on July 4, 2025. The company is evaluating the impact on deferred tax balances and financial statements.
- Risk Factors: Key risks include dependence on third-party manufacturers (one supplier accounts for ~23% of revenue), concentration of sales (Walmart ~22%, Amazon ~12%), and global economic volatility affecting input costs and demand.
Investor Verification Checklist
- Verify the timeline and closing conditions for the $100 million Pillar5 Pharma acquisition.
- Monitor the resolution of "Clear Eyes" supply shortages and their impact on Q2 and Q3 revenue recovery.
- Assess the impact of the newly enacted OBBBA tax legislation on future effective tax rates.
- Review the company's ability to maintain fixed charge ratio covenants given the $1 billion debt load.
- Track the remaining $213.7 million share repurchase authorization and execution pace.